Rani Therapeutics Holdings, Inc. (RANI): restructuring charge — Rani Therapeutics cuts workforce 25%, extends cash runway into 2025; reports preliminary Q3 net loss $17-19M

Rani Therapeutics Holdings, Inc.

2023-Q3 EPS reported $1.06

Workforce reduced ~25%; restructuring cost ~$0.3M (nearly all cash) expected Q4 2023, complete by Q1 2024.
Cash, cash equivalents and marketable securities ~$60.5M at Sept 30, 2023; cash runway extended into 2025.
Preliminary Q3 net loss $17-19M (vs $16.2M in Q3 2022); nine-month net loss $53-55M.
RT-102 Phase 2 starts Q4 2023; RT-111 Phase 1 topline Q1 2024; RaniPill HC Phase 1-ready H2 2024.
RT-101 discontinued; RT-105 and RT-110 paused; new 33,340 sq ft lease in Fremont at $95,019/month base rent.

item 1.01 item 2.02 item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Rani Therapeutics Holdings, Inc. reported the third quarter ended September 30, 2023 results: net income between $17.0 million and $19.0 million.

Period: the third quarter ended September 30, 2023
Net income: between $17.0 million and $19.0 million
Result: preliminary results

Exact text from the filing

Rani’s preliminary consolidated financial results for the third quarter ended September 30, 2023

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Rani Therapeutics Holdings, Inc. entered into Standard Industrial/Commercial Multi-Tenant Lease - Net with BKM South Bay 240, LLC valued at $95,019.00 per month (effective 2023-11-01).

Action: entry
Agreement: lease
Counterparty: BKM South Bay 240, LLC
Value: $95,019.00 per month
Effective: 2023-11-01

Exact text from the filing

On November 1, 2023, Rani Therapeutics, LLC (“Rani LLC”), a subsidiary of Rani Therapeutics Holdings, Inc. (the “Company”), and BKM South Bay 240, LLC (“Landlord”) entered into the Standard Industrial/Commercial Multi-Tenant Lease - Net (the “Lease”).

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Rani Therapeutics Holdings, Inc. announced a restructuring with charges of approximately $0.3 million (reduction of the Company’s workforce by approximately 25%).

Type: restructuring
Charge: approximately $0.3 million
Headcount: reduction of the Company’s workforce by approximately 25%

Exact text from the filing

On November 1, 2023, the Company committed to the Restructuring, which is a plan for strategic prioritization of its programs, expansion of its manufacturing and streamlining of its business operations to support potential near-term value drivers and long-term growth. The Restructuring provides for a reduction of the Company’s workforce by approximately 25%. As a result of the Restructuring, the Company estimates that it will incur approximately $0.3 million in costs of which nearly all are cash expenditures related to severance.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-057420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.